Leerink initiated coverage of Galapagos with a Market Perform rating and $24 price target. The firm notes Galapagos is in the midst of reinventing itself following clinical and commercial/regulatory setbacks, and thinks the company has yet to introduce promising shots on goal within its pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Biotech Alert: Searches spiking for these stocks today
- Galapagos announces FDA clearance of ATALANTA-1 IND application
- Galapagos price target lowered to EUR 30 from EUR 35 at Deutsche Bank
- BridGene Biosciences broadend deal with Galapagos to develop PROTAC
- GLPG Earnings Report this Week: Is It a Buy, Ahead of Earnings?